Institution
Cross Cancer Institute
- 178running trials
- 74closed trials
- 6,588publications (OpenAlex)
Running trials
Not yet recruiting
Study of Belantamab Mafodotin, Cevostamab, Pomalidomide for RRMM Patients (MAPLE)
Not yet recruiting
PSMA-PET Directed Radiation Therapy for High-Risk Prostate Cancer
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
Recruiting
Recruiting
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Feasibility of Prospective Surveillance and Early Physical Therapy for Trismus
Recruiting
Active, not recruiting
Recruiting
Recruiting
Recruiting
Active, not recruiting
Recruiting
Active, not recruiting
A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Prophylactic Mesalamine to Prevent Colitis Following Treatment With Ipilimumab/Nivolumab (Ipi/Nivo)
Recruiting
Prehab Prior to Stem Cell Transplantation in Multiple Myeloma
Recruiting
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
Recruiting
Recruiting
Active, not recruiting
Active, not recruiting
Recruiting
Recruiting
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
Recruiting
Showing 50 of 178.
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Lung cancer24 recruiting
- Multiple myeloma11 recruiting
- Melanoma8 recruiting
- Colorectal cancer7 recruiting
- Pancreatic cancer7 recruiting
- Prostate cancer7 recruiting
- Head and neck cancer6 recruiting
- Diffuse large B-cell lymphoma4 recruiting
- Triple-negative breast cancer4 recruiting
- Bladder cancer3 recruiting
- Cervical cancer3 recruiting
- Childhood cancers3 recruiting
- Endometrial cancer3 recruiting
- Gastric and oesophageal cancer3 recruiting
- Mantle cell lymphoma3 recruiting
- Chronic lymphocytic leukaemia2 recruiting
- Follicular lymphoma2 recruiting
- Glioblastoma2 recruiting
- Kidney cancer2 recruiting
- Metastatic breast cancer2 recruiting
- Ovarian cancer2 recruiting
- Acute lymphoblastic leukaemia1 recruiting
- Brain metastases1 recruiting
- Neuroendocrine tumours1 recruiting
- Sarcoma1 recruiting
- Thyroid cancer1 recruiting
Closed trials
Terminated
A Study of [18]F-PSMA-1007 in Patients With Known or Suspected Metastatic Prostate Cancer
Completed
Terminated
Completed
Terminated
A Nutritional Supplement to Support People With Non-small Cell Lung Cancer
Recruiting
Completed
Terminated
Neoadjuvant Combination of Atezolizumab/Bevacizumab Versus Neoadjuvant Radiation Therapy
Terminated
Completed
Completed
Completed
Terminated
Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma
Completed
Completed
Terminated
Completed
Completed
Completed
Completed
Terminated
Completed
Terminated
Terminated
Terminated
Completed
Completed
SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer
Completed
Completed
Completed
Completed
Terminated
Completed
Completed
Terminated
Completed
Terminated
A Study to Try to Bring Back Radioiodine Sensitivity in Patients With Advanced Thyroid Cancer.
Completed
Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas
Completed
Terminated
Metformin in Patients Initiating ADT as Prevention and Intervention of Metabolic Syndrome
Terminated
Completed
Completed
Completed
Completed
Completed
Completed
Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
Completed
Completed
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)
Completed
Showing 50 of 74.
Registry name variants (42)
Trial registries list this institution under these names. Each row is one registry entry: its address and the trials registered under it.
Cross Cancer Institute
Edmonton, T6G 1Z2
202 trials
University of Alberta - Cross Cancer Institute
Edmonton, Alberta T6G 1Z2
6 trials
Cross Cancer Institute (University of Alberta)
Edmonton, Alberta T6G 1Z2
4 trials
Cross Cancer Institute (Site 0201)
Edmonton, Alberta T6G 1Z2
2 trials
Cross Cancer Institute (Site 0207)
Edmonton, Alberta T6G 1Z2
2 trials
Cross Cancer Institute (Site 0291)
Edmonton, Alberta T6G 1Z2
2 trials
Contact: Study Coordinator
Contact: Study Coordinator
Cross Cancer Institute, Alberta
Edmonton, Alberta T6G 1Z2
1 trial
Contact: Matthew Anaka, MD
Cross Cancer Institute-Department of Medical Oncology (Site 0207)
Edmonton, Alberta T6G 1Z2
1 trial
Cross Cancer Institute /ID# 203114
Edmonton, Alberta T6G 1Z2
1 trial
Cross Cancer Institute. /ID# 246717
Edmonton, Alberta T6G 1Z2
1 trial
Cross Cancer Institute /ID# 249080
Edmonton, Alberta T6G 1Z2
1 trial
Cross Cancer Institute. /ID# 252065
Edmonton, Alberta T6G 1Z2
1 trial
Cross Cancer Institute /ID# 268984
Edmonton, Alberta T6G 1Z2
1 trial
Cross Cancer Institute /ID# 269392
Edmonton, Alberta T6G 1Z2
1 trial
Cross Cancer Institute /ID# 271504
Edmonton, Alberta T6G 1Z2
1 trial
Contact: Rebekah Taylor
Cross Cancer Institute. /ID# 272711
Edmonton, Alberta T6G 1Z2
1 trial
Cross Cancer Institute (Site 0010)
Edmonton, Alberta T6G 1Z2
1 trial
Cross Cancer Institute (Site 0033)
Edmonton, Alberta T6G 1Z2
1 trial
Cross Cancer Institute (Site 0057)
Edmonton, Alberta T6G 1Z2
1 trial
Cross Cancer Institute (Site 0064)
Edmonton, Alberta T6G 1Z2
1 trial
Cross Cancer Institute (Site 0105)
Edmonton, Alberta T6G 1Z2
1 trial
Cross Cancer Institute (Site 0110)
Edmonton, Alberta T6G 1Z2
1 trial
Cross Cancer Institute (Site 0111)
Edmonton, Alberta T6G 1Z2
1 trial
Cross Cancer Institute (Site 0183)
Edmonton, Alberta T6G 1Z2
1 trial
Cross Cancer Institute (Site 0203)
Edmonton, Alberta T6G 1Z2
1 trial
Contact: Study Coordinator
Cross Cancer Institute (Site 0205)
Edmonton, Alberta T6G 1Z2
1 trial
Contact: Study Coordinator
Cross Cancer Institute (Site 0206)
Edmonton, Alberta T6G 1Z2
1 trial
Cross Cancer Institute (Site 0216)
Edmonton, Alberta T6G 1Z2
1 trial
Cross Cancer Institute (Site 0281)
Edmonton, Alberta T6G 1Z2
1 trial
Cross Cancer Institute (Site 0313)
Edmonton, Alberta T6G 1Z2
1 trial
Cross Cancer Institute (Site 0332)
Edmonton, Alberta T6G 1Z2
1 trial
NCT06136624Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
Contact: Study Coordinator
Cross Cancer Institute (Site 0400)
Edmonton, Alberta T6G 1Z2
1 trial
Cross Cancer Institute (Site 0407)
Edmonton, Alberta T6G 1Z2
1 trial
Contact: Study Coordinator
Cross Cancer Institute (Site 0408)
Edmonton, Alberta T6G 1Z2
1 trial
Cross Cancer Institute (Site 0513)
Edmonton, Alberta T6G 1Z2
1 trial
Cross Cancer Institute (Site 0614)
Edmonton, Alberta T6G 1Z2
1 trial
Cross Cancer Institute (Site 1104)
Edmonton, Alberta T6G 1Z2
1 trial
Cross Cancer Institute (Site 1414)
Edmonton, Alberta T6G 1Z2
1 trial
Cross Cancer Institute (Site 3004)
Edmonton, Alberta T6G 1Z2
1 trial
Duplicate_Cross Cancer Institute /ID# 204540
Edmonton, Alberta T6G 1Z2
1 trial
Duplicate_Cross Cancer Institute /ID# 213838
Edmonton, Alberta T6G 1Z2
1 trial
University of Alberta - Cross Cancer Institute (CCI)
Edmonton, Alberta T6G 1Z2
1 trial
Contact: Clinical Trials
Conditions
Diseases this institution publishes on or runs trials for.
- Multiple myeloma22 works · 31 trials
Institution data: ROR 00m3k3802 (CC0-1.0)Updated 15 Nov 2026